Article
FDA advisory group likes Macugen but delays formal vote for now
New York-Members of the FDA's advisory committee reviewing pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration say they are "impressed" with the drug but declined to take a formal vote.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
